Last reviewed · How we verify
Dental spray "BUCCOTHERM"
BUCCOTHERM is a dental spray marketed by I.M. Sechenov First Moscow State Medical University, currently holding a niche position in the oral care segment. The key composition patent for BUCCOTHERM is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential entry of generic competitors post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Dental spray "BUCCOTHERM" |
|---|---|
| Sponsor | I.M. Sechenov First Moscow State Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: